A5109583465- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Global Cancer Incidence and Screening
- Women's cancer prevention and management
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Cancer survivorship and care
- Health Systems, Economic Evaluations, Quality of Life
- T-cell and B-cell Immunology
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Advances in Oncology and Radiotherapy
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Acute Lymphoblastic Leukemia research
Hospital Santa Izabel
2022-2024
Fleury S.A. (Brazil)
2019-2024
Centro de Pesquisas Oncológicas
2020-2024
Instituto de Oncologia do Paraná
2023
Sociedade Brasileira de Oncologia Clínica
2020-2022
Secretaria da Educação do Estado da Bahia
2016-2021
Centro Brasileiro de Estudos em Dermatologia
2020
AC Camargo Hospital
2018
Hospital de Clínicas de Porto Alegre
2018
Real Hospital Português
2018
The COVID-19 pandemic affected health care systems globally and resulted in the interruption of usual many facilities, exposing vulnerable patients with cancer to significant risks. Our study aimed evaluate impact this on worldwide.
IntroductionAccess to targeted therapies for lung cancer depends on the accurate identification of patients' biomarkers through molecular testing. The International Association Study Lung Cancer (IASLC) conducted an international survey evaluate perceptions current practice and barriers implementation testing.MethodsWe distributed IASLC members other health care professionals around world. included a seven-question introduction all respondents, who then answered according one three tracks:...
To compare the effectiveness and side effects of methadone morphine as first-line treatment with opioids for cancer pain.Patients in international palliative care clinics pain requiring initiation strong were randomly assigned to receive (7.5 mg orally every 12 hours 5 4 needed) or (15 sustained release needed). The study duration was weeks.A total 103 patients (49 group 54 group). groups had similar baseline scores pain, sedation, nausea, confusion, constipation. Patients receiving more...
Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib capecitabine for locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) -negative breast cancer.Patients were randomly assigned to first- second-line 1,000 mg/m(2) orally twice day days 1 14 of every 21-day cycle 400 mg placebo. The primary end point was progression-free survival (PFS).In total, 229...
In response to the COVID-19 pandemic, ASCO launched a Global Webinar Series address various aspects of cancer care during pandemic. Here we present lessons learned and recommendations that have emerged from these webinars.Fifteen international health experts different global regions oncology disciplines participated in one six 1-hour webinars discuss latest data, share their experiences, provide manage These sessions include didactic presentations followed by moderated discussion questions...
Breast cancer (BC) in young women is uncommon and tends to present with more aggressive characteristics. To better understand characterize this scenario Brazil through real-world data, we performed a subanalysis of AMAZONA III study (ClinicalTrials.gov identifier: NCT02663973).The (GBECAM 0115) prospective registry that included 2,950 newly diagnosed invasive BC from January 2016 until March 2018 at 22 sites. Valid data were obtained 2,888 patients regarding age diagnosis complete baseline...
New cases of the novel coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome 2 (SARS-CoV-2), continue to rise worldwide following declaration a pandemic by World Health Organization (WHO). The current has completely altered workflow health services worldwide. However, even during this critical period, patients with other diseases, like cancer, need be properly treated. A few reports have shown that mortality due SARS-CoV-2 is higher in elderly and those active...
Low rates of germline genetic testing (GGT) for breast cancer (BC) have been reported globally, with limited data from low- and middle-income countries (LMICs). In this study, we used real-world to assess the GGT rate BC in an LMIC identified barriers its use. We analyzed 2,974 newly diagnosed patients AMAZONA III largest Brazilian multicenter, prospective cohort. were determined entire cohort high-risk hereditary group (HR), defined by National Comprehensive Cancer Network criteria, between...
O câncer se tornou uma das principais causas de morte no mundo desde a segunda metade do século XX, com aumento da incidência e mortalidade, inclusive em indivíduos jovens. Paralelamente, avanços terapêuticos, especialmente na imunoterapia, transformaram o tratamento oncológico ao modular resposta imune contra os tumores. A eficácia dessas terapias, entanto, depende fortemente microambiente tumoral. Esta revisão aborda racional para desenvolvimento testes diagnósticos disbiose intestinal uso...
COVID-19 has affected cancer care worldwide. Clinical trials are an important alternative for the treatment of oncologic patients, especially in Latin America, where can be only opportunity some them to access novel and, sometimes, standard treatments.
Abstract Background The aim of this study was to carry out a descriptive analysis the somatic genetic profile and co‐occurring mutations non‐small cell lung cancer (NSCLC) samples from patients tested with comprehensive genomic profiling (CGP). Methods This retrospective cross‐sectional diagnosed NSCLC 2013 2018 in Brazil whose were submitted CGP (FoundationOne or FoundationACT) using either tumor circulating DNA (ctDNA) plasma. Results We recovered 513 results patients, 457 (89.1%) which...
When interleukin-2 (IL-2) binds to the IL-2 receptor (IL2-R) on activated T cells, a soluble portion of (sIL2-R) is released. After allogeneic bone marrow transplantation (BMT), serum concentration sIL2-R may, therefore, be useful surrogate marker for cell activation that results in acute graft-versus-host disease (aGVHD). To determine if help establish diagnosis aGVHD, serial concentrations were measured weekly 4 weeks 43 patients after BMT. Grafts from HLA-matched siblings (n = 33), 5/6 3)...
PURPOSE There is a paucity of consistent data concerning genetic mutations in Brazilian patients with lung cancer. The aim this study was to retrospectively analyze epidermal growth factor receptor (EGFR) detected real-world scenario using large cohort non–small-cell cancer (NSCLC). MATERIALS AND METHODS This cross-sectional, observational, descriptive on the basis database EGFR molecular analysis from tumor samples confirmatory histopathological diagnosis primary Specimens were collected...
IntroductionStage III NSCLC is a heterogeneous disease, representing approximately one-third of newly diagnosed lung cancers. Brazil lacks detailed information regarding stage distribution, treatment patterns, survival, and prognostic variables in locally advanced NSCLC.MethodsRELANCE/LACOG 0118 an observational, retrospective cohort study assessing sociodemographic clinical data patients with having from January 2015 to June 2019, regardless received. The was conducted across 13 cancer...